Pegfilgrastim + Plinabulin + Docetaxel, doxorubicin, and cyclophosphamide (TAC)
Phase 3UNKNOWN 0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 24
Phase 35
ApprovedIndication / Disease
Chemotherapy-induced Neutropenia
Conditions
Chemotherapy-induced Neutropenia
Trial Timeline
Oct 23, 2019 → Sep 25, 2025
NCT ID
NCT03294577About Pegfilgrastim + Plinabulin + Docetaxel, doxorubicin, and cyclophosphamide (TAC)
Pegfilgrastim + Plinabulin + Docetaxel, doxorubicin, and cyclophosphamide (TAC) is a phase 3 stage product being developed by BeyondSpring for Chemotherapy-induced Neutropenia. The current trial status is unknown. This product is registered under clinical trial identifier NCT03294577. Target conditions include Chemotherapy-induced Neutropenia.
What happened to similar drugs?
3 of 20 similar drugs in Chemotherapy-induced Neutropenia were approved
Approved (3) Terminated (4) Active (14)
🔄Hetrombopag Olamine + Hetrombopag Olamine ；Hetrombopag Olamine PlaceboJiangsu Hengrui MedicinePhase 3
Hype Score Breakdown
Clinical
17
Activity
4
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03294577 | Phase 3 | UNKNOWN |
Competing Products
20 competing products in Chemotherapy-induced Neutropenia